LLY Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
23.0B
+16.0%
19.8B
+2.6%
19.3B
+9.6%
17.6B
+13.1%
15.6B
Cost of Revenue
3.3B
-8.6%
3.6B
+6.1%
3.4B
+12.1%
3.0B
+22.9%
2.4B
Gross Profit
19.7B
+21.5%
16.2B
+1.9%
15.9B
+9.1%
14.6B
+11.3%
13.1B
Operating Expenses
10.7B
+46.8%
7.3B
-3.2%
7.5B
+4.4%
7.2B
+15.8%
6.2B
R&D
3.8B
+8.8%
3.5B
-7.7%
3.8B
+9.7%
3.5B
+3.9%
3.3B
SG&A
3.4B
+16.9%
2.9B
-6.3%
3.1B
+14.3%
2.7B
-0.4%
2.8B
Operating Income
9.0B
+0.7%
8.9B
+6.5%
8.4B
+13.7%
7.4B
+7.3%
6.9B
EBITDA
13.0B
+26.3%
10.3B
+7.5%
9.6B
+8.1%
8.9B
+18.1%
7.5B
Net Income
7.1B
-4.1%
7.4B
+11.4%
6.6B
+18.9%
5.6B
-1.4%
5.7B
EPS (Basic)
$7.95
-3.9%
$8.27
+11.6%
$7.41
+19.1%
$6.22
-1.3%
$6.30
EPS (Diluted)
$7.94
-3.9%
$8.26
+11.8%
$7.39
+19.0%
$6.21
-1.3%
$6.29
Shares (Diluted)
893.7M
-0.2%
895.9M
-0.2%
898.0M
-0.1%
898.8M
-0.1%
899.8M
Eli Lilly & (LLY) โ€” Financials